BET inhibitor - Pipeline Insight, 2022
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “BET inhibitor - Pipeline Insight, 2022” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in BET inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
BET inhibitor: Overview
Bromodomain and extraterminal domain (BET) proteins are epigenetic molecules that regulate the expression of multiple genes involved in carcinogenesis. The advent of potent inhibitors of BET proteins (BETi), which target either one or both bromodomains, represents an important step towards the goal of suppressing oncogenic networks within tumours.
BET-family members influence cell cycle progression by activating oncogenes such as MYC, JUNB, CCND1 and CCNA1. Consistent with a role in regulating the expression of cell cycle genes, knockdown of BRD4 leads to arrest in S phase in some cell types.17 BET proteins may directly activate oncogene transcription through recruitment to hyper-acetylated regulatory regions, as is seen is the regions surrounding MYC and CCNA1 genes. Upon being recruited to chromatin, BET-family members engage the mediator complex, which in turn, interacts with the core transcription machinery. Mediator provides a platform for the association of the pTEFb complex, leading to the phosphorylation of RNA POL II on serine 2, acting as a catalyst for transcriptional elongation.
Development of BET inhibitors that disrupt BET protein binding to acetylated lysine residues of chromatin and suppress transcription of various oncogenes has shown promising results in breast cancer cells and xenograft models. Overall, BET inhibitors constitute a promising field of clinical search in hematologic malignancies and solid tumors. Breast cancer heterogeneity creates a therapeutic challenge that needs to be addressed by new therapeutic options. Results from ongoing studies remain to prove if BET inhibition can serve this purpose.
Report Highlights
This segment of the BET inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
BET inhibitor Emerging Drugs
It is currently in phase III stage of development for the treatment of Myelofibrosis and is being developed by Constellation Pharmaceuticals.
It is currently in phase III stage of development is being developed by Resverlogix.
Further product details are provided in the report……..
BET inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different BET inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
BET inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses BET inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging BET inhibitor drugs.
BET inhibitor Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “BET inhibitor - Pipeline Insight, 2022” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in BET inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
BET inhibitor: Overview
Bromodomain and extraterminal domain (BET) proteins are epigenetic molecules that regulate the expression of multiple genes involved in carcinogenesis. The advent of potent inhibitors of BET proteins (BETi), which target either one or both bromodomains, represents an important step towards the goal of suppressing oncogenic networks within tumours.
BET-family members influence cell cycle progression by activating oncogenes such as MYC, JUNB, CCND1 and CCNA1. Consistent with a role in regulating the expression of cell cycle genes, knockdown of BRD4 leads to arrest in S phase in some cell types.17 BET proteins may directly activate oncogene transcription through recruitment to hyper-acetylated regulatory regions, as is seen is the regions surrounding MYC and CCNA1 genes. Upon being recruited to chromatin, BET-family members engage the mediator complex, which in turn, interacts with the core transcription machinery. Mediator provides a platform for the association of the pTEFb complex, leading to the phosphorylation of RNA POL II on serine 2, acting as a catalyst for transcriptional elongation.
Development of BET inhibitors that disrupt BET protein binding to acetylated lysine residues of chromatin and suppress transcription of various oncogenes has shown promising results in breast cancer cells and xenograft models. Overall, BET inhibitors constitute a promising field of clinical search in hematologic malignancies and solid tumors. Breast cancer heterogeneity creates a therapeutic challenge that needs to be addressed by new therapeutic options. Results from ongoing studies remain to prove if BET inhibition can serve this purpose.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence BET inhibitor R&D. The therapies under development are focused on novel approaches for BET inhibitor.
This segment of the BET inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
BET inhibitor Emerging Drugs
- Pelabresib: Constellation Pharmaceuticals
It is currently in phase III stage of development for the treatment of Myelofibrosis and is being developed by Constellation Pharmaceuticals.
- Apabetalone: Resverlogix
It is currently in phase III stage of development is being developed by Resverlogix.
Further product details are provided in the report……..
BET inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different BET inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on BET inhibitor
- Phases
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
BET inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses BET inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging BET inhibitor drugs.
BET inhibitor Report Insights
- BET inhibitor Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing BET inhibitor drugs?
- How many BET inhibitor drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for BET inhibitor?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the BET inhibitor therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for BET inhibitor and their status?
- What are the key designations that have been granted to the emerging drugs?
- Resverlogix
- Constellation Pharmaceuticals
- Zenith Epigenetics
- AbbVie
- Bristol-Myers Squibb
- Daiichi Sankyo Company
- Nuvation Bio
- TG therapeutics
- Apabetalone
- Pelabresib
- ZEN-3694
- ABBV-744
- CC-95775
- PLX-2853
- NUV-868
- TG-1601
- BMS-986158
Introduction
Executive Summary
BET inhibitor: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
BET inhibitor– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
BET inhibitor companies’ collaborations, Licensing, Acquisition -Deal Value Trends
BET inhibitor Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Pelabresib: Constellation Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
ZEN-3694: Zenith Epigenetics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
CC-95775: Bristol-Myers Squibb
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
NUV-868: Nuvation Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
BET inhibitor Key Companies
BET inhibitor Key Products
BET inhibitor- Unmet Needs
BET inhibitor- Market Drivers and Barriers
BET inhibitor- Future Perspectives and Conclusion
BET inhibitor Analyst Views
BET inhibitor Key Companies
Appendix
Executive Summary
BET inhibitor: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
BET inhibitor– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
BET inhibitor companies’ collaborations, Licensing, Acquisition -Deal Value Trends
BET inhibitor Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Pelabresib: Constellation Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
ZEN-3694: Zenith Epigenetics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
CC-95775: Bristol-Myers Squibb
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
NUV-868: Nuvation Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
BET inhibitor Key Companies
BET inhibitor Key Products
BET inhibitor- Unmet Needs
BET inhibitor- Market Drivers and Barriers
BET inhibitor- Future Perspectives and Conclusion
BET inhibitor Analyst Views
BET inhibitor Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for BET inhibitor
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for BET inhibitor
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for BET inhibitor
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for BET inhibitor
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
